In 2005, Dan co-founded and served as President and CEO of Inviragen Inc., which he transformed from a virtual start - up to a global clinical stage company with sites in Colorado, Wisconsin and Singapore and translated two vaccines from the research bench to human clinical trials, including one for dengue feve
In 2005, Dan co-founded and served as President and CEO of Inviragen Inc., which he transformed from a virtual start - up to a
global clinical stage company with sites
in Colorado, Wisconsin and Singapore and translated two vaccines from the research bench to human clinical trials, including one for dengue feve
in Colorado, Wisconsin and Singapore and translated two vaccines from the research bench to
human clinical trials, including one for dengue fever.
Dr. Falk is also PI of an NIH, pharma, and philanthropic funded translational research laboratory group at CHOP that investigates the causes and
global metabolic consequences of mitochondrial disease, as well as targeted therapies,
in C. elegans, zebrafish, mouse, and
human tissue models of genetic - based respiratory chain dysfunction, and directs multiple
clinical treatment
trials in mitochondrial disease patients.